---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-004721"
form_type: "8-K"
ticker: "INKT"
cik: "0001840229"
company_name: "MiNK Therapeutics, Inc."
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:49:17.606259+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# MiNK Q2 net loss narrows to $2.7M; cash $9.3M; clinical programs advance

## Summary
- Net loss Q2 2024 $2.7M ($0.07/sh) vs $6.2M ($0.18/sh) Q2 2023; 6-month loss $6.5M vs $11.9M.
- Cash $9.3M at Jun 30, up from $3.4M at Dec 31; cash used in ops $2.3M for Q2, reduced from $4.2M YoY.
- Closed $5.8M PIPE at 25% premium to new investor; cash runway extended into 2025.
- AgenT-797: Phase 2 gastric cancer advancing, early data at upcoming conference; Phase 1 GvHD activation planned; ARDS expanded access shows clinical benefit.

## SEC filing metadata
- accession: 0001171843-24-004721
- form_type: 8-K
- ticker: INKT
- cik: 0001840229
- company_name: MiNK Therapeutics, Inc.
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840229/000117184324004721/0001171843-24-004721-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840229/000117184324004721/f8k_081324.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-004721
- JSON: https://secwatch.observer/filing/0001171843-24-004721.json
- Plain text: https://secwatch.observer/filing/0001171843-24-004721.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.